Avidity engineering of human heavy-chain-only antibodies mitigates neutralization resistance of SARS-CoV-2 variants

Emerging SARS-CoV-2 variants have accrued mutations within the spike protein rendering most therapeutic monoclonal antibodies against COVID-19 ineffective. Hence there is an unmet need for broad-spectrum mAb treatments for COVID-19 that are more resistant to antigenically drifted SARS-CoV-2 variants...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Wenjuan Du, Rick Janssens, Anna Z. Mykytyn, Wentao Li, Dubravka Drabek, Rien van Haperen, Marianthi Chatziandreou, Melanie Rissmann, Joline van der Lee, Melissa van Dortmondt, Itziar Serna Martin, Frank J. M. van Kuppeveld, Daniel L. Hurdiss, Bart L. Haagmans, Frank Grosveld, Berend-Jan Bosch
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Frontiers Media S.A. 2023-02-01
Serie:	Frontiers in Immunology
Soggetti:	heavy-chain-only antibody avidity SARS-CoV-2 antibody-mediated neutralization neutralization escape
Accesso online:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1111385/full
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!